Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 201–300 of 799
Sadovnik, I., Herrmann, H., Eisenwort, G., Blatt, K., Hoermann, G., Mueller, N., Sperr, W. R., & Valent, P. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.003 · Cited by 39
“In CML, the intrinsic form of re sistance is common to most or all LSC and is considered to be at least in part indepe ndent of BCR-ABL1 [9-12].”
InfluentialAl-Rikabi, R. H., Al-Shmgani, H. S., Dewir, Y. H., & El-Hendawy, S. (2020) · Molecules · doi:10.3390/molecules25030478 · Cited by 41
“Blocking IL-33 could be a potential therapy that allow reducing cytokine-mediated malignant stem cell [13] as well as drug resistance [14].”
BackgroundABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives
Massimino, M., Stella, S., Tirrò, E., Pennisi, M. S., Vitale, S. R., Puma, A., Romano, C., Gregorio, S. D., Tomarchio, C., Raimondo, F. D., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14215 · Cited by 44
Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells
Brown, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032373 · Cited by 42
“For example, chronic myeloid leukemia arises in a hematopoietic stem cell, and the leukemia stem cells are resistant to the tyrosine kinase inhibitors that are used to treat this disease [9].”
MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction
Asmussen, J. K., Lasater, E. A., Tajon, C. A., Osés-Prieto, J. A., Jun, Y., Taylor, B. S., Burlingame, A. L., Craik, C. S., & Shah, N. P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0235 · Cited by 46
Treatment-free remission in patients with chronic myeloid leukemia
Réa, D., & Cayuela, J. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2295-0 · Cited by 43
Mu, H., Zhu, X., Jia, H., Zhou, L., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643382 · Cited by 43
“Moreover, these and other studies (40, 45, 46) strongly suggest that the survival and proliferation of CML LSCs under TKI treatment occurs through BCR-ABL kinase-independent pathways (Figure 1).”
BackgroundAgarwal, P., Li, H., Choi, K., Hueneman, K. M., He, J., Welner, R. S., Starczynowski, D. T., & Bhatia, R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109386 · Cited by 43
“LSC resistance has been shown to be mediated by kinase-independent mechanisms (Corbin et al., 2011; Hamilton et al., 2012; Perl and Carroll, 2011).”
Mizoguchi, I., Yoshimoto, T., Katagiri, S., Mizuguchi, J., Tauchi, T., Kimura, Y., Inokuchi, K., Ohyashiki, J. H., & Ohyashiki, K. (2013) · Cancer Science · doi:10.1111/cas.12216 · Cited by 45
Lin, H., Chen, M., Rothe, K., Lorenzi, M. V., Woolfson, A., & Jiang, X. (2014) · Oncotarget · doi:10.18632/oncotarget.2353 · Cited by 39
“Recent studies have indicated that CML LSCs might not be exclusively dependent on BCR-ABL TK activity for their survival [18, 19].”
Chorzalska, A. D., Ahsan, N., Rao, R. S. P., Roder, K., Yu, X., Morgan, J. W., Tepper, A., Hines, S., Zhang, P., Treaba, D. O., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12186 · Cited by 39
“, 2010), and the observed abundance of Tpl2-derived phosphopeptides in our Bcr-Abl1-independent model of IM resistance, we evaluated transcript levels of MAP3K8 in CML CD34+ cells subjected to a 7-day exposure to 5 lM IM (Corbin et al., 2011; Holtz et al., 2005; Jiang et al., 2010).”
BackgroundMethodMechanisms controlling the anti-neoplastic functions of FoxO proteins
Hou, T., Li, Z., Zhao, Y., & Zhu, W. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.007 · Cited by 40
“In parallel, FoxO3-induced expression of BCL6 is required for protection and maintenance of CML LICs, LICs are insensitive to selective inhibitor of the BCR-ABL tyrosine kinase imatinib, a highly effective therapy for CML, and pharmacological inhibition of BCL6 leads to LICs apoptosis and upregulates sensitivity of CM…”
BackgroundCayssials, É., Jacomet, F., Piccirilli, N., Lefèvre, L., Roy, L., Guilhot, F., Chomel, J., Leleu, X. P., Gombert, J., Herbelin, A., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15858 · Cited by 39
“Consequently, for the majority of patients, the persistence of residual leukaemic cells necessitates lifelong TKI therapy (Corbin et al, 2011).”
BackgroundHupfeld, T., Chapuy, B., Schrader, V., Beutler, M., Veltkamp, C., Koch, R., Cameron, S., Aung, T., Haase, D., LaRosee, P., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12246 · Cited by 37
“Experiments have indicated that CML stem cells are quiescent in nature and do not depend on BCR-ABL1 activity for survival (Holyoake et al, 1999; Graham et al, 2002; Corbin et al, 2011).”
BackgroundSHP2 is required for BCR-ABL1-induced hematologic neoplasia
Gu, S. S., Sayad, A., Chan, G., Yang, W., Lu, Z., Virtanen, C., Etten, R. A. V., & Neel, B. G. (2017) · Leukemia · doi:10.1038/leu.2017.250 · Cited by 42
Nair, R. R., Tolentino, J. H. G., Argilagos, R. F., Zhang, L., Pinilla-Ibarz, J. A., & Hazlehurst, L. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.12.002 · Cited by 43
“Similar to our observation, Corbin et al showed that survival of CML stem and progenitor cells was BCR-ABL independent and so these cells were not sensitive to BCR-ABL kinase inhibitor-induced cell death [13].”
BackgroundResultInfluentialBCR: a promiscuous fusion partner in hematopoietic disorders
Peiris, M. N., Li, F., & Donoghue, D. J. (2019) · Oncotarget · doi:10.18632/oncotarget.26837 · Cited by 44
Silvestri, G., Trotta, R., Stramucci, L., Ellis, J. J., Harb, J. G., Neviani, P., Wang, S., Eisfeld, A., Walker, C. J., Zhang, B., et al. (2020) · Blood Cancer Discovery · doi:10.1158/0008-5472.bcd-19-0039 · Cited by 38
“In fact, persistence of CML-initiating quiescent leukemic stem cells (qLSC) likely depends on their innate and acquired TKI resistance (3) and on impaired natural killer (NK) cell cytotoxicity against leukemic stem cells (LSC) (4), and accounts for disease relapse and dismal outcome (1, 5).”
BackgroundSelf-citationTargeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Soverini, S., Santis, S. D., Monaldi, C., Bruno, S., & Mancini, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137093 · Cited by 39
“It was later found that these cells are not killed by TKIs since they do not depend upon BCR-ABL1 kinase activity for their survival [24,25].”
BackgroundCarrà, G., Torti, D., Crivellaro, S., Panuzzo, C., Taulli, R., Cilloni, D., Guerrasio, A., Saglio, G. N., & Morotti, A. (2016) · Oncotarget · doi:10.18632/oncotarget.11507 · Cited by 45
Yang, H., Zeng, Q., He, Z., Wu, D., & Li, H. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112962 · Cited by 37
Patterson, S. D., & Copland, M. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00688-6 · Cited by 43
Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Ichim, C. V. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0159 · Cited by 35
Mtss1 is a critical epigenetically regulated tumor suppressor in CML
Schemionek, M., Herrmann, O., Reher, M. M., Chatain, N., Schubert, C., Costa, I. G., Hänzelmann, S., Gusmao, E. G., Kintsler, S., Braunschweig, T. A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.329 · Cited by 40
Hypoxia‐inducible micro RNA ‐210 regulates the DIMT 1‐ IRF 4 oncogenic axis in multiple myeloma
Ikeda, S., Kitadate, A., Abe, F., Saitoh, H., Michishita, Y., Hatano, Y., Kawabata, Y., Kitabayashi, A., Teshima, K., Kume, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13183 · Cited by 38
Liu, C., Nie, D., Li, J., Du, X., Lu, Y., Li, Y., Zhou, J., Jin, Y., & Pan, J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1733 · Cited by 39
Airiau, K., Mahon, F., Josselin, M., Jeanneteau, M., Turcq, B., & Belloc, F. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.01.004 · Cited by 35
Bamodu, O. A., Kuo, K.-T., Yuan, L.-P., Cheng, W.-H., Lee, W., Ho, Y., Chao, T.-Y., & Yeh, C. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.07.017 · Cited by 35
“These findings are consistent with and corroborate others highlighting the non-responsiveness of CD34+/CD38- cells to IM treatment [18,19].”
ResultThe Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis
Wu, X., Wu, Y., & Gong, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873903 · Cited by 36
“However, TKI resistance is still a challenge for CML patients and increases the risk of transfer to AML (68).”
BackgroundBedel, A., Pasquet, J., Lippert, É., Taillepierre, M., Lagarde, V., Dabernat, S., Dubus, P. R., Charaf, L., Béliveau, F., de Verneuil, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071596 · Cited by 35
“Recent studies indicate that their survival could be BCR-ABL1-independent [1,6].”
BackgroundResultBmi1 reprograms CML B-lymphoid progenitors to become B-ALL–initiating cells
Sengupta, A., Ficker, A. M., Dunn, S. K., Madhu, M., & Cancelas, J. A. (2011) · Blood · doi:10.1182/blood-2011-06-359232 · Cited by 37
Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia
Landry, B. K., Valencia‐Serna, J., Gül-Uludağ, H., Jiang, X., Janowska‐Wieczorek, A., Brandwein, J. M., & Uludağ, H. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.13 · Cited by 39
Preclinical approaches in chronic myeloid leukemia: from cells to systems
Clarke, C. J., & Holyoake, T. L. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.11.005 · Cited by 44
Deregulation of All-Trans Retinoic Acid Signaling and Development in Cancer
Brown, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512089 · Cited by 38
“For some years, investigators have looked to target therapies to cancer stem cells that are quiescent because they are resistant to conventional chemotherapeutics [90,91].”
BackgroundSuknuntha, K., Ishii, Y., Tao, L., Hu, K., McIntosh, B. E., Yang, D. T., Swanson, S. A., Stewart, R. M., Wang, J. Y. J., Thomson, J. L., et al. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.10.015 · Cited by 35
“Consistent with previous studies (Bellodi et al., 2009; Corbin et al., 2011), imatinib had little effect on somatic LTC-ICs.”
InfluentialKiyota, M., Kuroda, J., Yamamoto‐Sugitani, M., Shimura, Y., Nakayama, R., Nagoshi, H., Mizutani, S., Chinen, Y., Sasaki, N., Sakamoto, N., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0882-y · Cited by 36
“TKIs [13–17], while various components of bone marrow microenvironment (BMME), i.”
BackgroundYahata, T., Ibrahim, A. A., Hirano, K.-I., Muguruma, Y., Naka, K., Hozumi, K., Vaughan, D. E., Miyata, T., & Ando, K. (2020) · Haematologica · doi:10.3324/haematol.2019.230227 · Cited by 34
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells
Zhou, S., Li, W., Xiao, Y., Zhu, X., Zhong, Z., Li, Q., Cheng, F., Zou, P., You, Y., & Zhu, X. (2020) · Leukemia · doi:10.1038/s41375-020-0824-y · Cited by 34
Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells
Zhang, H., & Li, S. (2013) · Protein & Cell · doi:10.1007/s13238-013-2115-0 · Cited by 34
“The development of BCR-ABL mutations renders resistance, but resistance to TKIs is frequently present in the absence of a detectable mutation in BCR-ABL (Corbin et al., 2011).”
BackgroundMethodInfluentialSchemionek, M., Spieker, T., Kerstiens, L., Elling, C., Essers, M. A. G., Trumpp, A., Berdel, W. E., Müller‐Tidow, C., & Koschmieder, S. (2011) · Leukemia · doi:10.1038/leu.2011.366 · Cited by 35
On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population
Traulsen, A., Lenaerts, T., Pacheco, J. M., & Dingli, D. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0810 · Cited by 34
“Let us consider the appearance of a mutation, say BCRABL, that has no impact on the reproduction of the HSCs [12–14,20].”
BackgroundPagani, I. S., Spinelli, O., Mattarucchi, E., Pirrone, C., Pigni, D., Amelotti, E., Lilliu, S., Boroni, C., Intermesoli, T., Giussani, U., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.65 · Cited by 33
“Hence they concluded that long-term IM treatment does not completely deplete the cell population that drives the disease [25, 44-47].”
Fan, L., Liu, C., Hu, A., Liang, J., Li, F., Xiong, Y., & Mu, C. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119179 · Cited by 33
Eit, R. E., Iskandarani, A., Saliba, J. L., Jabbour, M. N., Mahfouz, R. A., Bitar, N., El-Ayoubi, H. R., Zaatari, G. S., Mahon, F., de Thé, H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28427 · Cited by 33
“Arsenic downregulates PML expression and forces CML LIC to enter the cell cycle, becoming more sensitive to therapy.12,24,25 Interferon alpha (IFN) has been extensively used for CML treatment patients in the preimatinib era.26 In vitro, it decreases the colony-forming capacity of cells from CML patients and has antipr…”
BackgroundInfluentialFlis, K., Irvine, D., Copland, M., Bhatia, R., & Skorski, T. (2012) · Leukemia & Lymphoma · doi:10.3109/10428194.2012.696313 · Cited by 32
“ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib may induce favorable therapeutic responses, but LSCs are intrinsically insensitive to TKIs despite the inhibition of BCR–ABL1 kinase [2].”
BackgroundClonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia
Majeti, R. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.10.003 · Cited by 37
“Such a scenario has been observed in chronic myelogenous leukemia (CML), where abl-kinase inhibitors are effective at killing progenitor cells leading to long-term remissions, but are ineffective at eradicating the HSC/LSC compartment [19].”
BackgroundSignal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
Ahmed, W. B., & Etten, R. A. V. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0150-1 · Cited by 44
“In part, the failure of TKIs to eradicate CML has been attributed to so-called leukemic stem cells (LSCs), pluripotent BCRABL1 progenitors that are largely quiescent [6] and resistant to killing by ABL1 inhibitors [7].”
BackgroundNaka, K., Ishihara, K., Jomen, Y., Jin, C. H., Kim, D., Gu, Y., Jeong, E., Li, S., Krause, D. S., Kim, D., et al. (2015) · Cancer Science · doi:10.1111/cas.12849 · Cited by 32
Avelino, K. Y. P. S., Frías, I. A. M., Lucena‐Silva, N., Gomes, R. G., de Melo, C. P., Oliveira, M. D. L., & Andrade, C. A. S. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.09.029 · Cited by 33
Is going for cure in chronic myeloid leukemia possible and justifiable?
Mahon, F. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.122.3798214 · Cited by 34
Ahn, J. S., Li, J., Chen, E., Kent, D. G., Park, H. J., & Green, A. R. (2015) · Oncogene · doi:10.1038/onc.2015.285 · Cited by 32
Vicente‐Dueñas, C., Hauer, J., Ruiz-Roca, L., Ingenhag, D., Rodríguez-Meira, A., Auer, F., Borkhardt, A., & Sánchez-García, I. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.001 · Cited by 32
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
Agarwal, A., MacKenzie, R. J., Besson, A., Jeng, S., Carey, A., LaTocha, D. H., Fleischman, A. G., Duquesnes, N., Eide, C. A., Vasudevan, K. B., et al. (2014) · Blood · doi:10.1182/blood-2013-04-497040 · Cited by 33
Self-citationGłodkowska‐Mrówka, E., Manda‐Handzlik, A., Stelmaszczyk‐Emmel, A., Seferyńska, I., Stokłosa, T., Przybylski, J., & Mrówka, P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.109 · Cited by 31
Soni, A., Pandey, C. M., Solanki, S., Kotnala, R. K., & Sumana, G. (2018) · Talanta · doi:10.1016/j.talanta.2018.05.038 · Cited by 31
Ahmed, W. B., & Etten, R. A. V. (2013) · Hematology · doi:10.1182/asheducation-2013.1.189 · Cited by 31
Chesnais, V., Arcangeli, M.-L., Delette, C., Rousseau, A., Guermouche, H., Lefèvre, C., Bondu, S., Diop, M. K., Cheok, M. H.-C., Chapuis, N., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707745 · Cited by 33
“8[1-35] 21[10-38] SF3B1 SF3B1 TET2 TET2 TET2 ASXL1 TET2 ASXL1 EZH2 CBL U2AF1 ASXL1 U2AF1”
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy
Réa, D., & Mahon, F. (2017) · British Journal of Haematology · doi:10.1111/bjh.14973 · Cited by 30
“…TKIs do not restore a fully normal haematopoietic compartment as quiescent BCR-ABL1+ leukaemia stem cells (LSC) do not depend on BCR-ABL1 activity for their survival and persist even during effective TKI treatment (Graham et al, 2002; Chu et al, 2011; Corbin et al, 2011; Hamilton et al, 2012).”
BackgroundSRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia
Sinnakannu, J. R., Lee, K. L., Cheng, S., Li, J., Yu, M., Tan, S. P., Ong, C. C. H., Li, H., Than, H., Anczuków, O., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0732-1 · Cited by 32
“Because exogenous cytokine signaling is known to confer impaired TKI sensitivity in CML cells [6, 12, 40, 41], we hypothesized that SRSF1 expression is required for cytokineinduced imatinib responsiveness.”
BackgroundNaka, K., Ochiai, R., Matsubara, E., Kondo, C., Yang, K., Hoshii, T., Araki, M., Araki, K., Sotomaru, Y., Sasaki, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18491-9 · Cited by 37
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Tanaka, Y., Takeda, R., Fukushima, T., Mikami, K., Tsuchiya, S., Tamura, M., Adachi, K., Umemoto, T., Asada, S., Watanabe, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27928-8 · Cited by 35
Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition
Kuo, Y., Qi, J., & Cook, G. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.02.007 · Cited by 31
“reduced proliferation of primitive CML LSCs, it has been unable to eliminate residue LSC populations that may be potential sources of relapse [49-52].”
BackgroundJin, Y., Yao, Y., Chen, L., Zhu, X., Jin, B., Shen, Y., Li, J., Du, X., Lu, Y., Jiang, S., et al. (2016) · Theranostics · doi:10.7150/thno.16139 · Cited by 30
“Interestingly, although LSCs are believed to originate from malignant transformation of HSCs triggered by BCR-ABL, the continual maintenance of an LSC pool in CML may be BCR-ABL–independent probably because of gain of additional oncogenic hits [15, 17].”
BackgroundDysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia
Basilico, S., & Göttgens, B. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1535-3 · Cited by 31
“The first evidence for a stem cell origin of cancer was demonstrated by Philip Fialkow in Chronic Myelogenous Leukaemia (CML) [48].”
BackgroundInfluentialThe rising prevalence of chronic myeloid leukemia in France
Delord, M., Foulon, S., Cayuela, J., Rousselot, P. H., & Bonastre, J. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.04.008 · Cited by 32
Gu, S. S., Chan, W. W., Mohi, G., Rosenbaum, J., Sayad, A., Lu, Z., Virtanen, C., Li, S., Neel, B. G., & Etten, R. A. V. (2016) · Blood · doi:10.1182/blood-2015-06-653006 · Cited by 30
Carter, B. Z., Mak, P. Y., Mu, H., Wang, X., Tao, W., Mak, D. H. F., Dettman, E. J., Cardone, M. H., Zernovak, O., Seki, T., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219261 · Cited by 31
“It is important to point out that although TKI are inactive against CML stem cells, they do inhibit BCR-ABL1 activity in these cells.(6) The balance of pro- and anti-apoptotic proteins decides cell death or survival.”
BackgroundPrecision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 30
Chen, Y., Zou, J., Cheng, F., & Li, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769730 · Cited by 32
“Evidence from several studies demonstrated that TKIs act mainly on highly proliferating leukemic cells but have modest effects on CML stem cells (LSCs), which can survive using kinase-independent mechanisms (90, 91).”
BackgroundYan, J., Yang, M., Zhang, X., Luo, C., Cheng-Kan, D. U., Jiang, Y., Dong, X.-J., Wang, Z.-M., Yang, L., Li, Y.-D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04842-5 · Cited by 36
Wu, L., Wu, Y. C., Chen, R., Liu, Y., Huang, L., Lou, L., Zheng, Z., Chen, Y., & Xu, J. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.180 · Cited by 29
Quintarelli, C., Angelis, B. D., Errichiello, S., Caruso, S., Esposito, N., Colavita, I., Raia, M., Pagliuca, S., Pugliese, N., Risitano, A. M., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.11.006 · Cited by 31
“However, both clinical and in vitro preclinical data, in which esidual BCR-ABL immature cells were isolated despite successful reatment with Imatinib mesylate [4], have shown that CML stem ell survival is not dependent on BCR-ABL kinase activity [6,8], nd that, consequently, BCR-ABL independent mechanisms may e respon…”
BackgroundEngineering Enzymatically Activated “Molecular Grenades” for Cancer
Denmeade, S. R., & Isaacs, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.562 · Cited by 31
Zarou, M. M., Rattigan, K. M., Sarnello, D., Shokry, E., Dawson, A., Ianniciello, A., Dunn, K. M., Copland, M., Sumpton, D. P., Vázquez, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46114-0 · Cited by 31
Pellicano, F., Mukherjee, L., & Holyoake, T. L. (2014) · Stem Cells · doi:10.1002/stem.1678 · Cited by 29
Moreno-Lorenzana, D., Avilés‐Vázquez, S., Esquivel, M. A. S., Alvarado‐Moreno, J. A., Ortiz-Navarrete, V. F., Torres-Martínez, H., Ayala‐Sánchez, M., Mayani, H., & Chávez‐González, A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1160976 · Cited by 28
“thus, its analysis could offer important information on CML stem cells biology and the effect of TKIs on primitive normal and CML cells.(23,24)”
BackgroundMuselli, F., Peyron, J., & Mary, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225616 · Cited by 28
“Furthermore, despite a continuous inhibition of BCR-ABL by TKIs (Imatinib, Dasatinib or Nilotinib), primary CML stem/progenitors are able to self-maintain in the presence of a cocktail of cytokines [72].”
BackgroundPyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
Rattigan, K. M., Brabcová, Z., Sarnello, D., Zarou, M. M., Roy, K., Kwan, R. S.-Y., de Beauchamp, L., Dawson, A., Ianniciello, A., Khalaf, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40222-z · Cited by 31
“Also contributing to TKI-resistance, BCR::ABL1 independent pathways 24 – 26 , suppression of BCR::ABL1 protein level but not gene expression in low oxygen tension typical of the bone marrow niche 27 , and contribution of the bone marrow niche cells 26 .”
BackgroundLiu, X., Rothe, K., Yen, R., Fruhstorfer, C., Maetzig, T., Chen, M., Forrest, D. L., Humphries, R. K., & Jiang, X. (2017) · Leukemia · doi:10.1038/leu.2017.108 · Cited by 28
Schubert, C., Allhoff, M., Tillmann, S., Maié, T., Costa, I. G., Lipka, D. B., Schemionek, M., Feldberg, K., Baumeister, J., Brümmendorf, T. H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0722-9 · Cited by 28
ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells
Yang, S., Zhu, X., Zhang, H., Yang, Q., Wei, Y.-S., Zhu, D., Liu, M.-D., Shen, S.-M., Li, X., He, P., et al. (2021) · Blood · doi:10.1182/blood.2020010400 · Cited by 30
“Combining ANP32B ablation with imatinib or p53 activator promotes eradication of CML LSCs BCR-ABL1 TKIs fail to eliminate LSCs in CML, which remains a potential source of relapse.(6,7,36) Given that ANP32B is essential for maintenance of LSCs, we examined the effects of combining ANP32B ablation with imatinib.”
BackgroundPeter, B., Eisenwort, G., Sadovnik, I., Bauer, K., Willmann, M., Rülicke, T., Berger, D., Stefanzl, G., Greiner, G., Hoermann, G., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26650 · Cited by 28
Curing Chronic Myeloid Leukemia
Réa, D., Rousselot, P. H., Guilhot, J., Guilhot, F., & Mahon, F. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0117-2 · Cited by 27
“demonstrated that LSC escape from TKI-induced cell death was likely to be BCR-ABL1-independent [36, 37].”
BackgroundC/EBPβ promotes BCR–ABL-mediated myeloid expansion and leukemic stem cell exhaustion
Hayashi, Y., Hirai, H., Kamio, N., Yao, H., Yoshioka, S., Miura, Y., Ashihara, E., Fujiyama, Y., Tenen, D. G., & Maekawa, T. (2012) · Leukemia · doi:10.1038/leu.2012.258 · Cited by 29
Lucas, C., Milani, M., Butterworth, M., Carmell, N., Scott, L. J., Clark, R. E., Cohen, G. M., & Varadarajan, S. (2016) · Leukemia · doi:10.1038/leu.2016.42 · Cited by 29
The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
Cheloni, G., Poteti, M., Bono, S., Masala, E., Mazure, N. M., Rovida, E., Lulli, M., & Sbarba, P. D. (2017) · Stem Cells International · doi:10.1155/2017/4979474 · Cited by 30
Willmann, M., Sadovnik, I., Eisenwort, G., Entner, M., Bernthaler, T., Stefanzl, G., Hadzijusufovic, E., Berger, D., Herrmann, H., Hoermann, G., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.012 · Cited by 27
Hematological malignancies: disease pathophysiology of leukemic stem cells.
Ramdass, B., Chowdhary, A. S., & Koka, P. S. (2013) · PubMed · Cited by 32
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
Ianniciello, A., Dumas, P., Drullion, C., Guitart, A. V., Villacreces, A., Peytour, Y., Chevaleyre, J., de la Grange, P. B., Vigon, I., Desplat, V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18904 · Cited by 26
Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells
Reddy, R. G., Bhat, U. A., Chakravarty, S., & Kumar, A. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04109-w · Cited by 26
Inzoli, E., Aroldi, A., Piazza, R., & Gambacorti-Passerini, C. B. (2022) · American Journal of Hematology · doi:10.1002/ajh.26556 · Cited by 30
“All the above-mentioned studies used an abrupt interruption of TKI.”
BackgroundInfluentialTakahashi, N., Kameoka, Y., Onizuka, M., Onishi, Y., Takahashi, F., Dan, T., Miyata, T., Ando, K., & Harigae, H. (2022) · Cancer Medicine · doi:10.1002/cam4.5292 · Cited by 27
Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Heo, S., Enriquez, L. D., Federman, S. M., Chang, A. Y., Mace, R., Shevade, K., Nguyen, P., Litterman, A. J., Shafer, S., Przybyla, L., et al. (2024) · Genome biology · doi:10.1186/s13059-023-03132-3 · Cited by 31
Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
Vicente‐Dueñas, C., Barajas-Diego, M., Romero-Camarero, I., González‐Herrero, I., Flores, T., & Sánchez-García, I. (2012) · Oncotarget · doi:10.18632/oncotarget.461 · Cited by 28
“This model not only faithfully recapitulates the human disease but also has been able to anticipate that human CML stem cells survival is Bcr-Abl kinase independent and suggest curative approaches in CML must focus on kinase-independent mechanisms of resistance [7, 27, 28].”
BackgroundOmacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
Li, S., & Chen, Y. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s41786 · Cited by 28
“20 31 Thus, a significant number of CML patients will take TKIs for the rest of their lives.”
Role of autophagy in the progression and suppression of leukemias
Ekiz, H. A., Can, G., & Baran, Y. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.03.009 · Cited by 26
“Thereore, because of this insensitivity tyrosine kinase inhibitors re unlikely to eliminate BCR/ABL(+) progenitors [41].”
BackgroundJabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.859074 · Cited by 26
Self-citationAnalysis of BCR/ABL transcripts in healthy individuals
Boquett, J. A., Alves, J. R. P., & de Oliveira, C. E. C. (2013) · Genetics and Molecular Research · doi:10.4238/2013.october.24.8 · Cited by 29
“Although the detection of low levels of BCR/ABL transcripts in CML patients is used in disease control strategies, new observations have demonstrated that malignant cell persistence is not necessarily dependent on higher activity in BCR/ABL signaling pathways (Jilani et al., 2008; Corbin et al., 2011; Nguyen et al., 2…”
BackgroundNovel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer
Chávez‐González, A., Bakhshinejad, B., Pakravan, K., Guzmán, M. L., & Babashah, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0297-1 · Cited by 26
“Thus, the dependence of CMLderived LSCs on pro-survival Bcl-2 family member signaling is a key factor to be considered for patients exhibiting resistance to TKIs [59].”
InfluentialShah, M., & Bhatia, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-97746-1_6 · Cited by 26
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.